In the ADVENT trial, pulsed field ablation, a new technology for terminating drug-refractory paroxysmal AF, was noninferior to conventional thermal ablation but had potential advantages.
12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9 Catheter
/PRNewswire/ Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that positive results.
/PRNewswire/ Conformal Medical, Inc. announced today the presentation of the one-year data from the company s initial left atrial appendage occlusion (LAAO).